Skip to main content

Table 2 Subjects’ baseline characteristics

From: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

  Placebo GH GH + Caf 25 GH + Caf 50 GH + Caf 75
Subject (Men/women) N = 14 (7/7) n = 15 (7/8) n = 15 (8/7) n = 15 (8/7) n = 15 (7/8)
Age (y) 49.4 ± 8.5 49.0 ± 10 49.1 ± 13 50.8 ± 9.8 47.3 ± 9.9
Height (cm) 163.7 ± 11 162.9 ± 9.7 162.0 ± 8.9 162.6 ± 8.4 162.6 ± 7.3
Body weight (g) 70.3 ± 9.6 70.0 ± 9.9 69.2 ± 9.0 70.5 ± 7.4 70.2 ± 6.5
BMI (kg/m2) 26.1 ± 1.1 26.2 ± 1.6 26.3 ± 1.2 26.7 ± 1.8 26.5 ± 1.2
Waist (cm) 90.9 ± 5.7 90.6 ± 3.0 90.4 ± 5.3 90.0 ± 4.7 91.0 ± 4.4
Hip (cm) 96.5 ± 5.1 96.8 ± 2.9 95.9 ± 4.4 97.1 ± 3.1 96.4 ± 4.6
Abdominal fat area      
 Total (cm2) 301.7 ± 50.6 304.3 ± 41.8 297.9 ± 54.8 295.1 ± 53.7 310.8 ± 43.9
 Visceral (cm2) 97.2 ± 53.1 97.6 ± 27.7 107.5 ± 42.3 108.1 ± 46.1 101.1 ± 28.9
 Subcutaneous (cm2) 204.6 ± 59.5 206.6 ± 45.4 190.4 ± 59.0 187.0 ± 48.0 209.8 ± 45.4
  1. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index
  2. Mean ± SD